Aldurazyme Market Report 2026

Aldurazyme Market Overview

• The Aldurazyme market growth in the historic period has been driven by limited treatment options for mps i, high morbidity from untreated gag accumulation • Market expansion is supported by growth in newborn screening programs, rising investment in rare disease therapies • Growth Driver: Impact Of Rising Clinical Trials On The Growth Of The Aldurazyme Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Aldurazyme Market?

Aldurazyme is a prescription medication classified as an enzyme replacement therapy (ERT). It is used to treat mucopolysaccharidosis type I (MPS I), a rare genetic disorder caused by a deficiency of the enzyme α-L-iduronidase. This enzyme is crucial for breaking down glycosaminoglycans (GAGs), substances that build up in the body and cause various health issues. It provides a synthetic form of the deficient enzyme, helping to reduce the accumulation of GAGs in the body's tissues and improving symptoms related to the disorder. The main types of indications for aldurazyme include Hurler syndrome, Hurler-Scheie, and Scheie. Hurler syndrome, also known as mucopolysaccharidosis type I (MPS I), is a rare genetic disorder caused by a deficiency of the enzyme alpha-L-iduronidase, leading to the accumulation of glycosaminoglycans in the body. It is distributed through various channels, including hospitals and clinics and retail pharmacies, and is used by pediatric, adult, and geriatric.

What Is The Aldurazyme Market Growth Forecast?

The growth in the forecast period can be attributed to growth in newborn screening programs, rising investment in rare disease therapies, improved patient survival rates, expansion of specialty care infrastructure, increased reimbursement support for orphan drugs. Major trends in the forecast period include rising adoption of enzyme replacement therapies, growing focus on rare genetic disorders, expansion of early diagnosis and treatment programs, increased long-term management of mps i, strengthening of specialized treatment centers.

Global Aldurazyme Market Segmentation

1) By Indication: Hurler Syndrome, Hurler-Scheie, Scheie 2) By Distribution Channel: Hospitals And Clinics, Retail Pharmacies 3) By End User: Pediatric, Adult, Geriatric

What Are The Drivers Of The Aldurazyme Market?

The increase in the number of clinical trials is expected to drive the growth of the aldurazyme market going forward. Clinical trials are research studies conducted to evaluate the safety, efficacy, and side effects of new treatments, drugs, or medical devices in human participants. The rise in clinical trials is driven by the growing demand for innovative treatments, advancements in medical research, and an increasing emphasis on personalized healthcare. Clinical trials positively impact aldurazyme by providing critical data on its safety, efficacy, and long-term benefits for patients with mucopolysaccharidosis type I, helping to refine treatment protocols and expand its clinical use. For instance, in February 2024, according to ClinicalTrials.gov, a US-based government web resource, the clinical trial result publications rose from 4,024 in 2022 to 5,063 in 2023. Therefore, the increase in the number of clinical trials is driving the growth of the aldurazyme industry. The rise in healthcare expenditure is expected to drive the growth of the aldurazyme market going forward. Healthcare expenditure refers to the total amount of financial resources spent on the provision and consumption of healthcare services, including medical treatments, infrastructure, and administrative costs. The rise in healthcare expenditure is primarily driven by increasing aging populations, advances in medical technology, and a higher prevalence of chronic diseases. The rise in healthcare expenditure increases funding and accessibility for specialized treatments such as Aldurazyme, driving demand for its use in managing lysosomal storage disorders. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared to growth of 0.9% in 2022. Government spending, which is the primary source of healthcare financing in the UK, totaled $302 billion in 2023, accounting for 81.9% of the country's overall healthcare expenditure. Therefore, the rise in healthcare expenditure will drive the aldurazyme industry.

Key Players In The Global Aldurazyme Market

Major companies operating in the aldurazyme market are BioMarin Pharmaceuticals Inc., Sanofi S.A.

What Are Latest Mergers And Acquisitions In The Aldurazyme Market?

In November 2023, Elliott Investment Management, a US-based investment management firm, acquired a stake in BioMarin for $1 billion. As a result of the acquisition, BioMarin is expected to undergo changes driven by Elliott's involvement, with the activist investor engaging in discussions about the company's future direction and operational improvements. BioMarin Pharmaceutical Inc. is a US-based manufacturer of aldurazyme.

Regional Insights

North America was the largest region in the aldurazyme market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Aldurazyme Market?

The aldurazyme market consists of sales of rare disease medications, vaccines, and endocrinology products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Aldurazyme Market Report 2026?

The aldurazyme market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the aldurazyme industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.